View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 11, 2020updated 13 Feb 2020 10:17am

Cepheid to develop automated molecular test for coronavirus

US-based firm Cepheid has announced it is developing an automated molecular test to detect the new coronavirus strain (2019-nCoV).


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.

US-based firm Cepheid has announced it is developing an automated molecular test to detect the new coronavirus strain (2019-nCoV).

The company moved to develop the test as a response to the recent outbreak in China. As of 10 February, the epidemic killed more than 1,000 people with global confirmed cases surging to around 43,000.

Cepheid test is for use on its GeneXpert Systems, expected to deliver point-of-care results in around 30 minutes. According to the company, they deploy 23,000 GeneXpert Systems worldwide.

Once finalised, Cepheid plans to seek Emergency Use Authorization from the US Food and Drug Administration, delivering the assay worldwide.

Cepheid chief medical and technology officer Dr David Persing said: “The emergence of the 2019-nCoV outbreak has put significant pressure on healthcare facilities.

“An accurate test with a rapid turnaround time delivered close to the patient will expedite diagnostic testing and help alleviate these pressures.

“We plan to leverage the design principles of our current Xpert Xpress Flu / RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and future pandemic coronavirus strains.”

In another development, Finnish company Mobidiag also initiated the development of Novodiag molecular diagnostic test. The test will work to identify new coronavirus 2019-nCoV, as well as other influenza viruses in 30 minutes.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network